Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;20(2):152-167.
doi: 10.1111/ajco.13941. Epub 2023 Mar 13.

The therapeutic effects of berberine for gastrointestinal cancers

Amirhossein Davoodvandi  1   2 , Sahand Sadeghi  3 , Seyed Mohammad Amin Alavi  4 , Seyedeh Shaghayegh Alavi  5 , Ameneh Jafari  6   7 , Haroon Khan  8 , Michael Aschner  9 , Hamed Mirzaei  3 , Mehran Sharifi  10 , Zatollah Asemi  3
Affiliations
Review

The therapeutic effects of berberine for gastrointestinal cancers

Amirhossein Davoodvandi et al. Asia Pac J Clin Oncol. 2024 Apr.

Abstract

Cancer is one of the most serious human health issues. Drug therapy is the major common way to treat cancer. There is a growing interest in using natural compounds to overcome drug resistance, adverse reactions, and target specificity of certain types of drugs that may affect several targets with fewer side effects and be beneficial against various types of cancer. In this regard, the use of herbal medicines alone or in combination with the main anticancer drugs is commonly available. Berberine (BBR), a nature-driven phytochemical component, is a well-known nutraceutical due to its wide variety of pharmacological activities, including antioxidant, anti-inflammatory, antibacterial, antifungal, antiparasitic, antidiabetic, antihypertensive, and hypolipidemic. In addition, BBR exerts anticancer activities. In present article, we summarized the information available on the therapeutic effects of BBR and its mechanisms on five types of the most prevalent gastrointestinal cancers, including esophageal, gastric, colorectal, hepatocarcinoma, and pancreatic cancers.

Keywords: berberine; gastrointestinal cancer; therapy.

PubMed Disclaimer

References

REFERENCES

    1. Vedeld HM, Goel A, Lind GE. Epigenetic biomarkers in gastrointestinal cancers: the current state and clinical perspectives. Semin Cancer Biol. 2018;51:36‐49.
    1. Ramos MFKP, Pereira MA, Yagi OK, et al. Surgical treatment of gastric cancer: a 10‐year experience in a high‐volume university hospital. Clinics. 2018;73:e543s.
    1. Goodarzi E, Beiranvand R, Naemi H, Momenabadi V, Khazaei Z. Worldwide incidence and mortality of colorectal cancer and human development index (HDI): an ecological study. World Cancer Res J. 2019;6:8.
    1. Ashtari S. Hepatocellular carcinoma in Asia: prevention strategy and planning. World J Hepatol. 2015;7(12):1708.
    1. Abnet CC, Arnold M, Wei W‐Q. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360‐373.

MeSH terms

LinkOut - more resources